Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT ID: NCT05492578
Last Updated: 2026-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
PHASE2/PHASE3
1663 participants
INTERVENTIONAL
2022-08-22
2029-01-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to characterize the safety and efficacy of amlitelimab in treated participants with moderate to severe atopic dermatitis (AD) who have previously been enrolled in an amlitelimab clinical trial. All participants will have visits during the treatment period every 4 weeks. Responder participants rolling over from EFC17599 and EFC17600, and responder participants enrolling through screening from DRI17366 will be initiated into drug withdrawal (with no drug administration) at LTS17367 baseline visit to monitor durability of treatment response. If these responder participants relapse during LTS17367, they will have treatment restored. Non-responder participants rolling over from EFC17599 or EFC17600, and non-responder participants enrolling through screening from DRI17366 will have treatment administration from LTS17367 baseline. Participants rolling over from DRI17366, SFY17915 and INT18404 will also have treatment administration from LTS17367 baseline.
Remote visits with home dosing are allowed for the purpose of study drug administration, when applicable. In the case of remote visit with home dosing, the participant or a caregiver may administer study drug after appropriate training. Alternatively, if needed, and based on the investigator's judgement, home visits with healthcare professional assistance or on-site study drug administration visits can be performed. Where participants discontinue amlitelimab permanently during LTS17367, safety follow up will be performed for a minimum of 140 days from the last amlitelimab administration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06130566
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
NCT06224348
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
NCT06181435
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Amlitelimab dose level 1
Subcutaneous injection as per protocol
Amlitelimab
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Topical corticosteroids
Pharmaceutical form: Topical Route of administration: Topical
Topical calcineurin inhibitors
Pharmaceutical form: Topical Route of administration: Topical
Oral corticosteroids
Pharmaceutical form: Oral Route of administration: Oral
Amlitelimab dose level 2
Subcutaneous injection as per protocol
Amlitelimab
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Topical corticosteroids
Pharmaceutical form: Topical Route of administration: Topical
Topical calcineurin inhibitors
Pharmaceutical form: Topical Route of administration: Topical
Oral corticosteroids
Pharmaceutical form: Oral Route of administration: Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amlitelimab
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Topical corticosteroids
Pharmaceutical form: Topical Route of administration: Topical
Topical calcineurin inhibitors
Pharmaceutical form: Topical Route of administration: Topical
Oral corticosteroids
Pharmaceutical form: Oral Route of administration: Oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participated in an amlitelimab clinical trial for moderate to severe AD and received study treatment, adequately completed the assessments required for the treatment period.
* Have reached the rollover timepoint to LTS17367 at the last visit of the treatment period of their feeder study SFY17915, INT18404, EFC17599, or EFC17600
* Participants in DRI17366 must only be enrolled from 1 of the following 3 groups:
* The first group: participants at Week 24 in the DRI17336 study who have not achieved an ≥ Eczema Area and Skin Severity Index (EASI)-75 and are Investigator Global Assessment (IGA) ≥ 2.
* The second group: participants entering LTS17367 between Week 28 and Week 52 of the feeder study, due to loss of clinical response in the part 2 of the feeder study. Timepoints for entering LTS17367 are Weeks 28, 32, 36, 40, 44, 48 or 52.
* The third group: participants at Week 24 in DRI17366 who have been re-randomized and who subsequently complete the study to Week 52, enter safety follow-up and experience worsening of their AD during safety follow-up.
* Participated in DRI17366 completing the previous study safety follow up (Week 68) and wish to re-initiate treatment with amlitelimab up to one year after the last visit
* Complied with the previous clinical trial protocol to the satisfaction of the investigator
* Body weight must be ≥25 kg
Exclusion Criteria
* Developed a medical condition that would preclude participation as described in the section for permanent discontinuation of the feeder study or LTS17367 protocol
* Known history of or suspected current significant immunosuppression, including history of invasive opportunistic infections or helminthic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration
* History of solid organ or stem cell transplant
* Any malignancies or history of malignancies prior to baseline (except for non-melanoma skin cancer that has been excised and completely cured for more than 5 years prior to baseline)
* Participants positive for human immunodeficiency virus (HIV); participants with any of the following results at Screening (Visit 1) or at any point during the feeder study: presence of HBsAg with or without HBV DNA PCR test, or presence of anti-HBc Ab or presence of anti-HBs Ab with positive HBV DNA PCR test; positive HCVAb confirmed by positive HCV RNA PCR test
* History (within last 2 years prior to baseline) of prescription drug or substance abuse, including alcohol, considered significant by the Investigator
* Participants with active TB, latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, non-TB mycobacterial infection, or who are at high risk of contracting TB (such as close contact with individuals with active or latent TB) or received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to screening
* Participants with an indeterminate or a confirmed positive IGRA test are excluded from the study unless all of the following conditions are met:
1. Have a history of prior documented completed chemoprophylaxis for latent TB infection (with a treatment regimen as per local guidelines), OR treated for active TB infection
2. Have been in written form approved for participation in the present trial by a TB specialist who ruled out latent or active TB infection or other mycobacterial infection in the participant
3. For whom review and approval from Sponsor have been granted are eligible
* Severe concomitant illness that would in the Investigator's opinion inhibit the participant's participation in the study, including for example, but not limited to, hypertension, renal disease, neurological conditions, heart failure and pulmonary disease
* Skin co-morbidity that would adversely affect the ability to undertake AD assessments (e.g., psoriasis, tinea corporis, lupus erythematosus) as per Investigator's judgment
* Any medical condition which, in the opinion of the Investigator may present an unreasonable risk to the study participant as a result of his/her participation in this clinical study, may make participant's participation unreliable, or may interfere with study assessments
* In the Investigator's opinion, medical conditions related to prior AD medications that have not healed/fully recovered for more than 2 weeks before screening visit, including, but not limited to, conjunctivitis, keratitis, eosinophilic conditions, arthralgia, herpes zoster, thrombosis
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Allervie Clinical Research - Birmingham- Site Number : 8401101
Birmingham, Alabama, United States
Cahaba Dermatology & Skin Health Center- Site Number : 8401066
Birmingham, Alabama, United States
Center for Dermatology and Plastic Surgery- Site Number : 8401119
Scottsdale, Arizona, United States
Scottsdale Clinical Trials- Site Number : 8401149
Scottsdale, Arizona, United States
Arkansas Research Trials- Site Number : 8401244
North Little Rock, Arkansas, United States
Orange County Clinical Trials- Site Number : 8401271
Anaheim, California, United States
Encino Research Center- Site Number : 8401042
Encino, California, United States
First OC Dermatology- Site Number : 8401025
Fountain Valley, California, United States
Center for Dermatology Clinical Research- Site Number : 8401018
Fremont, California, United States
Sunwise Clinical Research- Site Number : 8401022
Lafayette, California, United States
Antelope Valley Clinical Trials- Site Number : 8401099
Lancaster, California, United States
Torrance Clinical Research - Narbonne Avenue- Site Number : 8401027
Lomita, California, United States
Long Beach Clinical Trials- Site Number : 8401188
Long Beach, California, United States
Dermatology Research Associates - Los Angeles- Site Number : 8401092
Los Angeles, California, United States
LA Universal Research Center- Site Number : 8401064
Los Angeles, California, United States
Cura Clinical Research - Oxnard- Site Number : 8401142
Oxnard, California, United States
Southern California Dermatology- Site Number : 8401043
Santa Ana, California, United States
Clinical Science Institute- Site Number : 8401028
Santa Monica, California, United States
Paradigm Clinical Research - Wheat Ridge- Site Number : 8401245
Wheat Ridge, Colorado, United States
Encore Medical Research of Boynton Beach- Site Number : 8401030
Boynton Beach, Florida, United States
St. Jude Clinical Research- Site Number : 8401287
Doral, Florida, United States
Alliance for Multispeciality Research - Fort Myers- Site Number : 8401111
Fort Myers, Florida, United States
Direct Helpers Research Center- Site Number : 8401056
Hialeah, Florida, United States
Doral Medical Research - Hialeah- Site Number : 8401094
Hialeah, Florida, United States
Clever Medical Research- Site Number : 8401160
Miami, Florida, United States
Medical Research Center of Miami II- Site Number : 8401019
Miami, Florida, United States
Acevedo Clinical Research Associates- Site Number : 8401088
Miami, Florida, United States
Sanchez Clinical Research- Site Number : 8401095
Miami, Florida, United States
Future Care Solution - Miami- Site Number : 8401144
Miami, Florida, United States
Florida International Research Center- Site Number : 8401091
Miami, Florida, United States
Savin Medical Group - Miami Lakes- Site Number : 8401085
Miami Lakes, Florida, United States
Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8401109
Miami Lakes, Florida, United States
K2 South Orlando - South Orange Avenue- Site Number : 8401268
Orlando, Florida, United States
Global Clinical Professionals (GCP)- Site Number : 8401045
St. Petersburg, Florida, United States
Clinical Research Trials of Florida- Site Number : 8401023
Tampa, Florida, United States
Alliance Clinical Research of Tampa- Site Number : 8401013
Tampa, Florida, United States
First Georgia Physician Group- Site Number : 8401190
Fayetteville, Georgia, United States
Aeroallergy Research Laboratory- Site Number : 8401004
Savannah, Georgia, United States
Northwestern University- Site Number : 8401038
Chicago, Illinois, United States
Equity Medical - Bowling Green- Site Number : 8401296
Bowling Green, Kentucky, United States
Skin Sciences- Site Number : 8401039
Louisville, Kentucky, United States
Velocity Clinical Research at The Dermatology Clinic - Baton Rouge- Site Number : 8401072
Baton Rouge, Louisiana, United States
MedPharmics - Covington- Site Number : 8401137
Covington, Louisiana, United States
BRCR Global Gretna- Site Number : 8401243
Gretna, Louisiana, United States
Revival Research Institute - Troy- Site Number : 8401012
Troy, Michigan, United States
Oakland Medical Center- Site Number : 8401116
Troy, Michigan, United States
Allergy & Immunology Associates of Ann Arbor- Site Number : 8401078
Ypsilanti, Michigan, United States
SKY Integrative Medical Center/SKYCRNG - Ridgeland- Site Number : 8401058
Ridgeland, Mississippi, United States
Skin Specialists- Site Number : 8401068
Omaha, Nebraska, United States
Pulmonology Group - Henderson- Site Number : 8401169
Henderson, Nevada, United States
The University of New Mexico- Site Number : 8401263
Albuquerque, New Mexico, United States
Equity Medical- Site Number : 8401239
New York, New York, United States
Skin Search Rochester- Site Number : 8401216
Rochester, New York, United States
Axis Clinical Trials- Site Number : 8401196
Fargo, North Dakota, United States
Best Skin Research - Camp Hill- Site Number : 8401031
Camp Hill, Pennsylvania, United States
Paddington Testing Company- Site Number : 8401041
Philadelphia, Pennsylvania, United States
Clinical Research of Philadelphia- Site Number : 8401193
Philadelphia, Pennsylvania, United States
Dermatology Associates of Plymouth Meeting- Site Number : 8401147
Plymouth Meeting, Pennsylvania, United States
Velocity Clinical Research - Columbia- Site Number : 8401176
Columbia, South Carolina, United States
Health Concepts - Site Number : 8401059
Rapid City, South Dakota, United States
Arlington Research Center- Site Number : 8401248
Arlington, Texas, United States
Modern Research Associates- Site Number : 8401093
Dallas, Texas, United States
Reveal Research Institute - Dallas- Site Number : 8401219
Dallas, Texas, United States
SMS Clinical Research- Site Number : 8401182
Mesquite, Texas, United States
Synapse Clinical Research - Missouri City- Site Number : 8401148
Missouri City, Texas, United States
Stryde Research - Epiphany Dermatology- Site Number : 8401185
Southlake, Texas, United States
Complete Dermatology - Sugar Land- Site Number : 8401061
Sugar Land, Texas, United States
Virginia Dermatology & Skin Cancer Center- Site Number : 8401047
Norfolk, Virginia, United States
Wyoming Research Foundation- Site Number : 8401234
Cheyenne, Wyoming, United States
Investigational Site Number : 0320006
Rosario, Santa Fe Province, Argentina
Investigational Site Number : 0320007
Rosario, Santa Fe Province, Argentina
Investigational Site Number : 0320011
Buenos Aires, , Argentina
Investigational Site Number : 0320016
Buenos Aires, , Argentina
Investigational Site Number : 0320008
Buenos Aires, , Argentina
Investigational Site Number : 0320010
Buenos Aires, , Argentina
Investigational Site Number : 0320002
Buenos Aires, , Argentina
Investigational Site Number : 0320004
Buenos Aires, , Argentina
Investigational Site Number : 0320009
Buenos Aires, , Argentina
Investigational Site Number : 0320019
Buenos Aires, , Argentina
Investigational Site Number : 0320005
Buenos Aires, , Argentina
Investigational Site Number : 0320014
Córdoba, , Argentina
Investigational Site Number : 0320013
Mendoza, , Argentina
Investigational Site Number : 0360010
Westmead, New South Wales, Australia
Investigational Site Number : 0360007
Woolloongabba, Queensland, Australia
Investigational Site Number : 0363002
Carlton, Victoria, Australia
Investigational Site Number : 0363003
Melbourne, Victoria, Australia
Investigational Site Number : 0360006
Melbourne, Victoria, Australia
Investigational Site Number : 0363001
Parkville, Victoria, Australia
Investigational Site Number : 0361006
Traralgon, Victoria, Australia
Centro de Pesquisas da Clínica IBIS- Site Number : 0760002
Salvador, Estado de Bahia, Brazil
PUC Trials- Nucleo de Pesquisa clinica da Escola de Medicina da PUCPR- Site Number : 0760023
Curitiba, Paraná, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760005
Porto Alegre, Rio Grande do Sul, Brazil
Faculdade de Medicina do ABC- Site Number : 0760001
Santo André, São Paulo, Brazil
Clinica de Alergia Martti Antila- Site Number : 0760006
Sorocaba, São Paulo, Brazil
CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760018
Rio de Janeiro, , Brazil
Hospital Alemao Oswaldo Cruz - São Paulo- Site Number : 0760010
São Paulo, , Brazil
Centro de Desenvolvimento em Estudos ClÌnicos Brasil- Site Number : 0760014
São Paulo, , Brazil
Investigational Site Number : 1002004
Pleven, , Bulgaria
Investigational Site Number : 1002005
Sofia, , Bulgaria
Investigational Site Number : 1002003
Sofia, , Bulgaria
Investigational Site Number : 1002006
Sofia, , Bulgaria
Investigational Site Number : 1002002
Sofia, , Bulgaria
Investigational Site Number : 1240039
Calgary, Alberta, Canada
Investigational Site Number : 1240019
Calgary, Alberta, Canada
Investigational Site Number : 1240023
Calgary, Alberta, Canada
Investigational Site Number : 1240016
Edmonton, Alberta, Canada
Investigational Site Number : 1240031
Edmonton, Alberta, Canada
Investigational Site Number : 1240040
Surrey, British Columbia, Canada
Investigational Site Number : 1240041
Winnipeg, Manitoba, Canada
Investigational Site Number : 1240033
Ajax, Ontario, Canada
Investigational Site Number : 1240014
Barrie, Ontario, Canada
Investigational Site Number : 1240020
Hamilton, Ontario, Canada
Investigational Site Number : 1240053
London, Ontario, Canada
Investigational Site Number : 1240017
London, Ontario, Canada
Investigational Site Number : 1241106
Markham, Ontario, Canada
Investigational Site Number : 1240018
Newmarket, Ontario, Canada
Investigational Site Number : 1241108
Niagara Falls, Ontario, Canada
Investigational Site Number : 1240034
Ottawa, Ontario, Canada
Investigational Site Number : 1240024
Richmond Hill, Ontario, Canada
Investigational Site Number : 1240021
Toronto, Ontario, Canada
Investigational Site Number : 1240012
Toronto, Ontario, Canada
Investigational Site Number : 1240026
Toronto, Ontario, Canada
Investigational Site Number: 1240035
Toronto, Ontario, Canada
Investigational Site Number : 1241107
Waterloo, Ontario, Canada
Investigational Site Number : 1241101
Windsor, Ontario, Canada
Investigational Site Number : 1240006
Québec, Quebec, Canada
Investigational Site Number: 1240028
Regina, Saskatchewan, Canada
Investigational Site Number : 1240036
Saskatoon, Saskatchewan, Canada
Investigational Site Number : 1520004
Valdivia, Los Ríos Region, Chile
Investigational Site Number : 1520013
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520008
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520003
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520010
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520005
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1560004
Beijing, , China
Investigational Site Number : 1560050
Changsha, , China
Investigational Site Number : 1560022
Chengdu, , China
Investigational Site Number : 1560043
Fuzhou, , China
Investigational Site Number : 1560021
Guangzhou, , China
Investigational Site Number : 1560025
Guangzhou, , China
Investigational Site Number : 1560036
Guangzhou, , China
Investigational Site Number : 1560058
Guangzhou, , China
Investigational Site Number : 1560044
Hangzhou, , China
Investigational Site Number : 1560002
Hangzhou, , China
Investigational Site Number : 1560006
Hangzhou, , China
Investigational Site Number : 1560029
Hangzhou, , China
Investigational Site Number : 1560024
Ningbo, , China
Investigational Site Number : 1560035
Ningbo, , China
Investigational Site Number : 1560001
Shanghai, , China
Investigational Site Number : 1560041
Shenyang, , China
Investigational Site Number : 1560026
Shenyang, , China
Investigational Site Number : 1560023
Wenzhou, , China
Investigational Site Number : 1560038
Wuhan, , China
Investigational Site Number : 1560003
Wuxi, , China
Investigational Site Number : 1560028
Zhenjiang, , China
Investigational Site Number : 2032108
Brno, , Czechia
Investigational Site Number : 2032106
Kutná Hora, , Czechia
Investigational Site Number : 2032105
Nový Jičín, , Czechia
Investigational Site Number : 2030010
Olomouc, , Czechia
Investigational Site Number : 2032104
Ostrava, , Czechia
Investigational Site Number : 2030009
Pilsen, , Czechia
Investigational Site Number : 2032102
Prague, , Czechia
Investigational Site Number : 2030008
Prague, , Czechia
Investigational Site Number : 2032101
Prague, , Czechia
Investigational Site Number : 2032103
Prague, , Czechia
Investigational Site Number : 2030011
Prague, , Czechia
Investigational Site Number : 2030006
Prague, , Czechia
Investigational Site Number : 2500008
Antony, , France
Investigational Site Number : 2500011
Bordeaux, , France
Investigational Site Number : 2500014
Clermont-Ferrand, , France
Investigational Site Number : 2500001
Lille, , France
Investigational Site Number : 2500012
Rouen, , France
Investigational Site Number : 2760009
Bad Bentheim, , Germany
Investigational Site Number : 2762203
Berlin, , Germany
Investigational Site Number : 2762202
Blankenfelde-Mahlow, , Germany
Investigational Site Number : 2761001
Dresden, , Germany
Investigational Site Number : 2762207
Gera, , Germany
Investigational Site Number : 2760017
Hamburg, , Germany
Investigational Site Number : 2762208
Kiel, , Germany
Investigational Site Number : 2761002
Lübeck, , Germany
Investigational Site Number : 2762201
Münster, , Germany
Investigational Site Number : 3000001
Athens, , Greece
Investigational Site Number : 3482303
Debrecen, , Hungary
Investigational Site Number : 3482306
Szolnok, , Hungary
Investigational Site Number : 3760005
Beersheba, , Israel
Investigational Site Number : 3760003
Jerusalem, , Israel
Investigational Site Number : 3760007
Tel Aviv, , Israel
Investigational Site Number : 3760008
Tel Litwinsky, , Israel
Investigational Site Number : 3800017
Naples, Napoli, Italy
Investigational Site Number : 3800016
Chieti, , Italy
Investigational Site Number : 3800021
Modena, , Italy
Investigational Site Number : 3800015
Perugia, , Italy
Investigational Site Number : 3800020
Torino, , Italy
Investigational Site Number : 3920007
Hiroshima, Hiroshima, Japan
Investigational Site Number : 3923114
Obihiro-Shi, Hokkaido, Japan
Investigational Site Number : 3923101
Sapporo, Hokkaido, Japan
Investigational Site Number : 3920006
Kobe, Hyōgo, Japan
Investigational Site Number : 3923108
Kagoshima, Kagoshima-ken, Japan
Investigational Site Number : 3920005
Sagamihara-shi, Kanagawa, Japan
Investigational Site Number : 3923113
Yokohama, Kanagawa, Japan
Investigational Site Number : 3920003
Kyoto, Kyoto, Japan
Investigational Site Number : 3923110
Sakai-shi, Osaka, Japan
Investigational Site Number : 3920002
Iruma-gun, Saitama, Japan
Investigational Site Number : 3923106
Shimotsuga-gun, Tochigi, Japan
Investigational Site Number : 3923112
Adachi-Ku, Tokyo, Japan
Investigational Site Number : 3923115
Chuo-Ku, Tokyo, Japan
Investigational Site Number : 3923104
Edogawa-Ku, Tokyo, Japan
Investigational Site Number : 3923107
Minato-Ku, Tokyo, Japan
Investigational Site Number : 3923105
Setagaya-Ku, Tokyo, Japan
Investigational Site Number : 3920001
Tachikawa-shi, Tokyo, Japan
Investigational Site Number : 3923109
Habikino-shi, , Japan
Investigational Site Number : 3923102
Kyoto, , Japan
Investigational Site Number : 3923113
Yokohama, , Japan
Investigational Site Number : 6162407
Krakow, Lesser Poland Voivodeship, Poland
Investigational Site Number : 6162409
Krakow, Lesser Poland Voivodeship, Poland
Investigational Site Number : 6162406
Krakow, Lesser Poland Voivodeship, Poland
Investigational Site Number: 6160010
Tarnów, Lesser Poland Voivodeship, Poland
Investigational Site Number : 6162414
Wroclaw, Lower Silesian Voivodeship, Poland
Investigational Site Number : 6162418
Wroclaw, Lower Silesian Voivodeship, Poland
Investigational Site Number : 6162417
Wroclaw, Lower Silesian Voivodeship, Poland
Investigational Site Number : 6162415
Lodz, Lódzkie, Poland
Investigational Site Number : 6162416
Lódz, Lódzkie, Poland
Investigational Site Number : 6162411
Warsaw, Masovian Voivodeship, Poland
Investigational Site Number : 6162413
Warsaw, Masovian Voivodeship, Poland
Investigational Site Number : 6162401
Rzeszów, Podkarpackie Voivodeship, Poland
Investigational Site Number : 6162419
Bialystok, Podlaskie Voivodeship, Poland
Investigational Site Number : 6162403
Gdansk, Pomeranian Voivodeship, Poland
Investigational Site Number : 6162402
Gdansk, Pomeranian Voivodeship, Poland
Investigational Site Number : 6160006
Gdansk, Pomeranian Voivodeship, Poland
Investigational Site Number : 6162404
Gdynia, Pomeranian Voivodeship, Poland
Investigational Site Number : 6162405
Katowice, Silesian Voivodeship, Poland
Investigational Site Number : 6162410
Szczecin, West Pomeranian Voivodeship, Poland
Investigational Site Number : 6162408
Krakow, , Poland
Investigational Site Number : 6160022
Lodz, , Poland
Investigational Site Number : 6162412
Warsaw, , Poland
Investigational Site Number : 6200004
Lisbon, , Portugal
Investigational Site Number : 6200001
Lisbon, , Portugal
Investigational Site Number : 6200003
Porto, , Portugal
Investigational Site Number : 6820001
Riyadh, , Saudi Arabia
Investigational Site Number : 7100015
Benoni, , South Africa
Investigational Site Number : 7100010
Cape Town, , South Africa
Investigational Site Number: 7100009
Claremont, , South Africa
Investigational Site Number : 7100012
Durban, , South Africa
Investigational Site Number : 7100001
Durban, , South Africa
Investigational Site Number : 4100012
Gwangju, Gwangju, South Korea
Investigational Site Number : 4100002
Ansan-si, Gyeonggi-do, South Korea
Investigational Site Number : 4100009
Suwon, Gyeonggi-do, South Korea
Investigational Site Number : 4100003
Yangsan, Gyeongsangnam-do, South Korea
Investigational Site Number : 4100015
Incheon, Incheon-gwangyeoksi, South Korea
Investigational Site Number : 4100013
Seoul, Seoul-teukbyeolsi, South Korea
Investigational Site Number : 4100007
Seoul, Seoul-teukbyeolsi, South Korea
Investigational Site Number : 4100010
Seoul, Seoul-teukbyeolsi, South Korea
Investigational Site Number : 4100006
Seoul, Seoul-teukbyeolsi, South Korea
Investigational Site Number : 4100011
Seoul, Seoul-teukbyeolsi, South Korea
Investigational Site Number : 4100008
Daegu, , South Korea
Investigational Site Number : 7240012
Las Palmas de Gran Canaria, Canary Islands, Spain
Investigational Site Number : 7240002
Badalona, Catalunya [Cataluña], Spain
Investigational Site Number : 7242504
Pontevedra, Galicia [Galicia], Spain
Investigational Site Number : 7240023
Burjassot - Valencia, Valenciana, Comunidad, Spain
Investigational Site Number : 7242505
Alicante, , Spain
Investigational Site Number : 7242501
Córdoba, , Spain
Investigational Site Number : 7240018
Granada, , Spain
Investigational Site Number : 7242503
Madrid, , Spain
Investigational Site Number : 1583201
Kaohsiung City, , Taiwan
Investigational Site Number : 1583202
Taichung, , Taiwan
Investigational Site Number : 1580001
Taipei, , Taiwan
Investigational Site Number : 1583203
Taoyuan, , Taiwan
Investigational Site Number : 7920005
Istanbul, , Turkey (Türkiye)
Investigational Site Number : 7920004
Kayseri, , Turkey (Türkiye)
Investigational Site Number : 7920008
Şahinbey, , Turkey (Türkiye)
Investigational Site Number : 7840001
Abu Dhabi, , United Arab Emirates
Investigational Site Number : 8260013
Bristol, Bristol, City of, United Kingdom
Investigational Site Number : 8260006
Glasgow, Glasgow City, United Kingdom
Investigational Site Number : 8260003
Portsmouth, Hampshire, United Kingdom
Investigational Site Number : 8260004
Leicester, Leicestershire, United Kingdom
Investigational Site Number : 8262603
London, London, City of, United Kingdom
Investigational Site Number : 8262601
London, London, City of, United Kingdom
Investigational Site Number : 8260010
Sutton in Ashfield, Nottinghamshire, United Kingdom
Investigational Site Number : 8260008
Liverpool, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
LTS17367 Plain Language Results Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1269-6490
Identifier Type: REGISTRY
Identifier Source: secondary_id
2023-506548-18
Identifier Type: REGISTRY
Identifier Source: secondary_id
KY1005-CT06
Identifier Type: OTHER
Identifier Source: secondary_id
2021-002344-73
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
LTS17367
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.